Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Companies / Japan

Astellas Hopes For Better In R&D

July 2006 | Project News

Japan's third-largest pharmaceutical firm, Astellas, is hoping to reverse a series of setbacks in its research pipeline. The company is aggressively pursuing in-licensing deals for promising new compounds, but has been forced to drop a number of potential candidates despite soaring investment in

Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.

[
: *
[
: *

Forgotten your password?

If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.

If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.

Related Insight Articles
Takeda Unveils Fresh R&D Spending Boost

Companies / Japan Leading Japanese drugmaker Takeda has announced a major increase in R&D spending, with local observers estimating that total research investment could amount to more than JPY1trn (US$8.59bn) over...
September 2006
Multinationals Eye Japan's Cancer Market

Companies / Japan According to industry experts, prospects for a significant expansion of Japan's US$3.2bn cancer market are set to improve significantly. New product launches by foreign-owned companies, and a health...
August 2006
Ranbaxy Launches Two Generics In Japan

Companies / Japan Nihon Pharmaceutical Industry, a joint venture between Ranbaxy and Nippon Chemipar, has launched the new products. Ranbaxy has also pledged to establish a wholly-owned subsidiary in
July 2006
Novartis Files Xolair In Japan

Companies / Japan Swiss drug major Novartis has filed its Xolair asthma treatment in Japan. If approved, the monoclonal antibody will be Japan's first-in-class therapy for severe forms of the respiratory disorder. Xolair...
July 2006
Japan's Tough Market To Separate Winners, Losers

Companies / Japan Heavy spending on product in-licensing and imminent patent expiries are set to bring mixed fortunes for Japan's leading drugmakers, according to local observers. In the coming years, the success of operations...
May 2006


All material on this site is protected by international copyright laws and use of this site is subject to our Terms & Conditions.
© 2009 Business Monitor International Ltd
Site powered by WORKSsitebuilder CMS